Background: Although investigations using Medicare claims files are ubiquitous in the health services research literature, Medicaid claims files are used less frequently. Nonetheless, Medicaid is the major payer for healthcare among low-income persons. Objective: To assess the added value of Medicaid claim files for identifying comorbid conditions and cancer treatments in a dually eligible sample. Research Design: Data were obtained from linked statewide tumor registries from 2 contiguous Midwestern states (Michigan and Ohio), Medicare and Medicaid enrollment files, and Medicare and Medicaid claims files. We estimated the prevalence of Charlson Comorbidity Index conditions by counting the number of patients with these conditions in the Medicare claims files alone. We then estimate the expected percent increase in the prevalence of comorbid conditions (along with the 95% confidence interval) that could be obtained by using both Medicare and Medicaid claim files. We followed a similar procedure to identify treatments provided to dually eligible patients. Results: Medicaid claims added very few individuals with comorbid conditions over those identified through Medicare claim files. The increase in the prevalence of comorbid conditions was between 0% and 2.5%. Likewise, Medicaid claims identified few individuals with cancer treatments who were not already identified through Medicare claim files, although variations were noted between the 2 states.
A lthough investigations using Medicare claim files are ubiquitous in the health services research literature, Medicaid claims files are used less frequently. Researchers must either access Medicaid files on a state-by-state basis or obtain Medicaid Analytic Extract files from the Centers for Medicare and Medicaid Services (CMS), which can be a costly option, 1 and one that could limit the possibility of linking Medicaid claim files with other sources of patient-level data (eg, disease registries).
Advantages of working with state Medicaid agencies include the ability to link with other files, complete patient enrollment and coverage information, and timely data. However, states vary in how they process and maintain Medicaid claim files and in their interest in and resources for working with researchers. Medicaid agencies may feel restricted in sharing their data given the current regulatory environment and privacy rules. If Medicaid data are obtained, there are many challenges associated with linking them to other files. [2] [3] [4] Nevertheless, Medicaid is the primary payer for certain categories of low-income people and for long-term nursing home care services 5 ; and until Medicare part D became available, Medicaid was the only source for prescription drug utilization for low-income individuals.
Using data from 2 contiguous Midwestern states, Michigan and Ohio, we examined the incremental value of Medicaid claim files for identifying comorbid conditions and cancer treatments among dually eligible Medicare and Medicaid beneficiaries. This assessment informs researchers who are weighing the potential gain from Medicaid claim files when studying dually eligible beneficiaries. Dually eligible beneficiaries are the most vulnerable among the elderly population, accounting for a disproportionate share of Medicaid and Medicare utilization and payments 6 and a disproportionate share of chronic illness relative to other Medicare enroll-ees. 7 However, many researchers base their assessment of healthcare utilization among dually eligible with Medicare claims alone without knowledge of how much Medicaid claims would have added to their analysis. 8 -12 We study the occurrence of comorbid conditions among the dually eligible because these conditions are negatively correlated with cancer treatment [13] [14] [15] [16] [17] and an accurate assessment of them is essential to fully understand disparities in cancer care. Disparities in treatment have been noted between dually eligible and Medicare-only patients diagnosed with cancer. 18 -20 However, if dually eligible beneficiaries receive care that is documented in Medicaid, but not Medicare claims, the extent of disparate treatment may be over-stated by analysts using Medicare claim files alone. Such an assessment is useful to researchers considering whether to expend resources to obtain Medicaid claim files.
METHODS

Data
Data were from linked statewide tumor registries, Medicare and Medicaid enrollment and claims files. These databases were developed independently by investigators in Michigan and Ohio. The studies, with their respective data users' agreement from the CMS, were approved by the Institutional Review Boards at Michigan State University, Michigan Department of Community Health, Virginia Commonwealth University for the Michigan part, and by the Ohio Department of Health, the Ohio Department of Job and Family Services, and University Hospitals of Cleveland for the Ohio part. The present study was carried out independently after investigators agreed on the study design and analytic strategies. Data by the respective parties were shared in aggregate only. The databases are described in greater detail elsewhere. 3, 4 Medicaid enrollment files were used to identify patients, aged 65 and older, dually eligible for Medicare and Medicaid. 
Sample
We selected all dually eligible patients diagnosed with female breast, colorectal, or prostate cancer between January 1, 1997 and December 31, 2000. These cancer sites and years of data were common to both states' datasets. Patients were continuously enrolled in Medicaid for at least 12 months before the month of diagnosis. We excluded patients who were not enrolled in Medicare parts A and B or were enrolled in a Health Maintenance Organization because claims data for these patients were not complete. For the comorbidity analysis, we required that patients be continuously enrolled in Medicare and Medicaid for the 12 months preceding cancer diagnosis (N ϭ 1107, Michigan and N ϭ 2435, Ohio). For the treatment analysis, the study population included patients continuously enrolled in Medicare and Medicaid for the 6 months after cancer diagnosis (N ϭ 2356, Michigan and N ϭ 2266, Ohio).
Comorbid Conditions
We used the Deyo et al 21 and Klablunde et al 22 adaptation of the Charlson Comorbidity Index, 23 which has been used to explain the probability and extent of cancer treatment. 22, 24 The comorbidity index included 13 conditions (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, diabetes, diabetes with complications, hemiplegia or paraplegia, and renal disease). There were no participants in the study population with severe liver disease or AIDS. Evidence of a malignancy was excluded because the sample was drawn from a cancer population. We created a summary category for "any comorbidity," which indicated the number of patients who had at least 1 of the 13 comorbid conditions. All inpatient, outpatient and physician Medicare and Medicaid claims for services rendered to patients in the year prior to diagnosis were used.
Treatment
We identified major cancer treatments for breast, colorectal, and prostate cancer for patients continuously dually enrolled in Medicare and Medicaid for 6 months after diagnosis. Michigan patients were diagnosed between January 1, 1997 and June 30, 2000 and Ohio patients were diagnosed between January 1, 1997 and December 31, 2000. We counted surgical, chemotherapy, and radiotherapy claims that occurred within 6 months after diagnosis in the inpatient, outpatient, and carrier files using International Classification of Disease (ICD-9), Current Procedural Terminology codes, and Healthcare Procedural Coding System. Surgical procedures included were breast biopsy, breast nodectomy, lumpectomy, mastectomy, colorectal biopsy, colorectal excision, colorectal resection, colorectal bypass, prostate biopsy, prostate nodectomy, prostatectomy, radical prostatectomy, and orchiectomy. The codes for these procedures and for chemotherapy and radiotherapy are included in an Appendix (Table A1 ).
Statistical Analysis
We identified the number of patients with comorbid conditions comprising the Charlson Comorbidity Index from the Medicare and Medicaid claim files alone. Next, we estimated the prevalence of these conditions by counting the number of new patients with these conditions in the Medicaid claim files and adding them to the number identified from Medicare claim files alone. Lastly, we estimated the percent increase in the calculated prevalence of comorbid conditions (along with the 95% confidence interval) that could be obtained by using Medicaid in addition to Medicare claim files. We followed a similar procedure to identify treatments provided to dually eligible patients.
All analyses were performed separately by state using SAS V9.1 (SAS institute Inc, Cary, NC). We combined the 3 cancer sites for the assessment of comorbid conditions, but kept the sites separate for the analysis of treatments. In all analyses, we report findings separately by state. Each state designs its own Medicaid program, with different services and reimbursement levels, which differentially affect providers and subsequent health care delivery to patients.
RESULTS
The Michigan and Ohio sample characteristics are reported in Table 1 . The Michigan sample was younger than the Ohio sample and had a higher percentage of males and African Americans (due to the higher prevalence of prostate cancer). Most of beneficiaries qualified for Medicare as "aged."
The number of individuals with comorbid conditions identified from Medicare claims alone, Medicaid claims alone, and Medicare and Medicaid claims is reported in Table  2 . The estimated condition-specific percent increase in the calculated prevalence, along with 95% confidence intervals that can be obtained from using both Medicare and Medicaid claims files is also reported. Approximately 64% and 69% of the Michigan and Ohio dually eligible patients, respectively, had at least 1 comorbid condition. Medicaid claims alone identified few patients with comorbid conditions. The highest percent prevalence increase for a single condition identified with Medicaid files was 2.2% (95% CI: 1.3-3.0) for congestive heart failure in Michigan. In Ohio, the highest percent prevalence increase was 2.5% (95% CI: 1.9 -3.1) for chronic obstructive pulmonary disease. When considering any comorbidity rather than a single condition, the percent prevalence increased by nearly 6% (95% CI: 4.4 -7.2) in Michigan and 4.5% (95% CI: 3.7-5.3) in Ohio by using Medicaid claims in addition to Medicare claims. Table 3 reports the cancer treatments identified from Medicare and Medicaid files. Medicaid claim files added less than 1% to the prevalence of cancer treatment identified from Medicare files alone in Michigan. The prevalence of breast biopsy was elevated slightly (2.4%) by the use of Ohio Medicaid claim files. Cancer treatment incidence increased slightly, ranging from 0.1% to 2.4% in Ohio and never exceeding 1% in Michigan, when Medicare files were supplemented with Medicaid files.
DISCUSSION
Medicaid claim files added few comorbid conditions and treatments that was found in Medicare claim files alone. Researchers may want to carefully consider whether Medicaid claims are worth the investment in time, dollars, and effort to supplement Medicare inpatient, outpatient, and carrier claims. According to the Centers for Medicare and Medicaid Services website that addresses third party liability, "the Medicaid program by law is intended to be the payer of last resort; that is, all other available third party resources must meet their legal obligation to pay claims before the Medicaid program pays for the care of an individual eligible for Medicaid." 25 Furthermore, Medicaid reimbursement rates may be below 80% of allowable charges reimbursed by Medicare. Therefore, Medicaid reimbursement, in many cases, may not be high enough to offset the administrative cost to submit the claims.
Other researchers examining the quality of Medicaid claim files report that Medicaid inpatient files greatly underreport hospitalizations in patients age 45 years and older. 26, 27 These researchers strongly urge others to obtain supplementary Medicare data in addition to Medicaid data for studies of dually eligible persons age 45 years and older. Our study reinforces this recommendation.
Three limitations are noteworthy. First, we examined only 2 states and although our findings were fairly consistent 28, 29 and to construct their enrollment history in Medicaid relative to an index date. The ability to identify dually eligible patients is of considerable value because they are very poor and have significant comorbid conditions that burden the Medicare and Medicaid systems. 6 In addition, studies have shown that dually eligible patients receive fewer cancer treatments and experience adverse outcomes relative to patients insured by Medicare alone. 3, 18 Our analysis provides guidance to researchers who study the dually eligible population. This study suggests that, relative to identifying comorbidities and cancer treatments, the incremental value of Medicaid inpatient, outpatient, and physician claims is small over what can be obtained from Medicare claims alone. 
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